MedTrace Logo

Therapeutic Plasma Exchange in MG

NCT01927692 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2015-07-16

No results posted yet for this study

Summary

The primary objective of the study is to longitudinally profile immunoglobulin levels and autoantibody levels in subjects with myasthenia gravis (MG) who receive therapeutic plasma exchange (TPE).

Conditions

Interventions

OTHER

Skin biopsy

An optional skin biopsy will be performed in up to 5 subjects at baseline and 2 weeks after therapeutic plasma exchange is completed.

OTHER

Single Fiber Electromyography

An optional SFEMG study will be performed at baseline and 2 weeks after therapeutic plasma exchange is completed.

Sponsors & Collaborators

Principal Investigators

  • Jeffrey Guptill, MD · Duke University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01927692 on ClinicalTrials.gov